Prokidney (PROK) Long-Term Deferred Tax (2022 - 2023)
Prokidney's (PROK) quarterly Long-Term Deferred Tax came in at $1.5 million in Q4 2023, down 15.12% year-over-year from $1.8 million in Q4 2022, and down 15.12% quarter-over-quarter from $1.8 million in Q4 2022.
Analysis
Prokidney (PROK) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Prokidney (PROK) has reported Long-Term Deferred Tax for 2 consecutive years, with $1.5 million the latest figure, recorded in Q4 2023.
- On a quarterly basis, Long-Term Deferred Tax fell 15.12% year-over-year to $1.5 million in Q4 2023; TTM through Dec 2023 was $1.5 million, a 15.12% decrease from a year earlier, with the FY2023 full-year figure at $1.5 million, down 15.12% from the prior year.
- Long-Term Deferred Tax was $1.5 million for Q4 2023 at Prokidney, down from $1.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $1.8 million in Q4 2022 and troughed at $1.5 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - |